Reports From the Field
New fast-acting insulin offers flexibility
Novo Nordisk A/S in Princeton, NJ, has received Food and Drug Administration approval for NovoLog, an insulin analog for treating diabetes. It has faster absorption, faster onset of action, and shorter duration of action than regular human insulin. The quick onset of blood sugar lowering after injection of NovoLog allows people with diabetes to inject themselves immediately before eating, offering greater flexibility to patients than regular human insulin, which must be injected 30 minutes before meals.